News Details
Roche launches NAVIFY Guidelines app to help clinicians easily access, personalise and document latest guidance for patients with the most common cancers
- NAVIFY Guidelines app pulls latest clinical guidance for breast, prostate, non-small-cell lung, colon and rectal (colorectal) cancers from the National Comprehensive Cancer Network® (NCCN®)
- Digitised process takes clinicians through each step of an intended course of treatment and allows them to enter deviations depending on an individual patient’s situation
- App alerts entire oncology care team to updates, integrates most recent content in their decision making process and facilitates documentation of intended personalised care plan
Basel, 21 October 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the release of its latest app as part of the NAVIFY Decision Support portfolio. The NAVIFY Guidelines app embeds the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) covering the four most common cancers within NAVIFY Tumor Board. When opening a patient case, the app identifies the appropriate guidelines based on the patient's cancer type. Clinicians can then select the intended pathway, easily click through the digitised decision tree or flowchart and personalise individual steps for a specific patient. The pathway is accessible to all tumour board participants, and can be exported to include in the practice’s EMR system, send to patients or submit for reimbursement approval by payers.
Guidelines in clinical practice help explain a disease and determine the optimal evidence-based treatment for individual patients based on their diagnosis, disease stage, age and other factors. In addition, clinical guidelines contribute to care management by promoting practice conformity and reducing cost.
Due to advances in medicine, NCCN Guidelines® are updated continuously. At the same time, with the move to more value-based care and respective payment models, clinicians face an increasing need for adhering to proven guideline recommendations. By digitising the guidelines process, alerting users real-time about new and updated guidelines and making the respective pathway available as part of the holistic patient dashboard in NAVIFY Tumor Board, the NAVIFY Guidelines app not only ensures that oncology care teams refer to latest information and are aligned regarding what is planned for the patient but also facilitates documentation.
"The NAVIFY Guidelines app provides clinicians with peace of mind that the latest clinical guidance has been considered in treatment decision making and monitoring. The ability to facilitate and track guidelines adherence, personalisation and documentation supports evidence-based care for patients around the globe. This latest addition to the NAVIFY ecosystem marks another step in supporting the move towards truly individualised care," said Thomas Schinecker, CEO Roche Diagnostics.
“Digitised guidelines available at point-of-care through clinical decision support software, such as the NAVIFY Guidelines app, help advance our mission of improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives and fits perfectly with our vision to define and advance high-quality, high-value cancer care across the world,” said Robert W. Carlson, MD, CEO NCCN.
The NAVIFY Guidelines app is available in the US, Canada, Singapore, Australia, New Zealand, Korea, Japan, Taiwan and Hong Kong.
Adding a new app to the NAVIFY ecosystem marks another step towards Roche’s personalised healthcare strategy ensuring the right treatment for the right patient at the right time.
About NCCN
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives.
About the NAVIFY Decision Support portfolio
The NAVIFY Decision Support portfolio helps healthcare professionals navigate the increasing complexity of medical practice by transforming large amounts of data into actionable insights - fundamentally changing clinical decision making across the care continuum. NAVIFY Tumor Board, a cloud-based software solution, streamlines and standardises preparation, facilitation and documentation of treatment decisions by oncology care teams. The NAVIFY Decision Support portfolio is continuously evolving to include additional solutions that support more personalised, confident treatment decisions for the benefit of each individual patient.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Communications Roche Diagnostics Information Solutions
Karin Erbacher
Phone: +41 79 561 0367 / e-mail: global.communications_dis@roche.com